Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Clinical Trials in Salt Lake City, Utah
2 recruitingSalt Lake City, Utah
Showing 1–2 of 2 trials
Recruiting
Phase 1Phase 2
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals181 enrolled31 locationsNCT07190300
Recruiting
Phase 2
Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
University of Utah160 enrolled1 locationNCT07216248